High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers.

Published in: Journal of clinical medicine (2022)

These data may inform the potential suitability of these cancers for immunotherapy and could guide the development of rational combination therapies based on immune checkpoint inhibitors with other targeted drugs.

Keyphrases

electronic health record
cancer therapy
big data
estrogen receptor
risk factors
human health
breast cancer cells
drug delivery
risk assessment
young adults
climate change
data analysis
deep learning